C12N 2795/10023
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2795/10023 (Virus like particles [vlp]) appears on 3 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 3
- Published applications
- 5
- Assignees
- 7
- Inventors
- 12
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Production and functionalization of nanoparticles derived from phage T5 and therapeutic uses13 Jan 2026US 12,521,432 B2Centre National de la Recherche Scientifique (CNRS)
- Theragnostic particles18 Feb 2020US 10,562,938 B2The Regents of the University of Colorado, a body corporate
- Theragnostic particles19 Sep 2017US 9,765,122 B2University of Washington through its Center for Commercialization
- Production and functionalization of nanoparticles derived from phage t5 and therapeutic uses22 Jun 2023US 2023/0190925 A1Centre National de la Recherche Scientifique (CNRS)
- Engineered bacteriophage t4 nanoparticles as a potential targeted activator of hiv-1 latency in cd4+ human t-cells26 Jan 2023US 2023/0026666 A1The Catholic University of America
- Theragnostic particles1 Mar 2018US 2018/0057542 A1University of Washington through its Center for Commercialization
- Theragnostic Particles26 Nov 2015US 2015/0337014 A1University of Washington through its Center for Commercialization
- Bacteriophage T4 Nanoparticles for Eukaryotic Delivery23 Aug 2012US 2012/0214867 A1The Government of the United States of America, as represented by the Secretary of the Navy
Most cited
By later US patents